Status:
NOT_YET_RECRUITING
The Role of Glucagon in Glucose Metabolism in Humans With and Without Bariatric Surgery
Lead Sponsor:
The University of Texas Health Science Center at San Antonio
Collaborating Sponsors:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Conditions:
Non-Diabetic
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
The goal of this study is to understand the role of glucagon signal on glucose metabolism in individuals with and without bariatric surgery. The study is involved with measuring glucose metabolism wit...
Detailed Description
Participants will be screened, and if eligible will be enrolled for metabolic studies for two separate aims. In aim 1, they undergo glucose clamp study with and without glucagon infusion. In aim 2, t...
Eligibility Criteria
Inclusion
- Provision of signed and dated informed consent form from participant.
- Male or female, ≤65 and ≥18 years old
- Subjects with history of gastric bypass surgery and sleeve gastrectomy more than a year since surgery and non-surgical subjects without history of gastrointestinal (GI) surgery
- HbA1c ≤6%
- Willing to adhere to the study intervention regimen
- Female subjects of childbearing potential must have a negative pregnancy test at screening and all the study visits, and must not be lactating
- Females of childbearing potential who are sexually active with a nonsterilized male partner must use at least one highly effective method of contraception from screening and must agree to continue using such precautions during the study.It is strongly recommended for the male partner of a female subject to also use male condom plus spermicide throughout this period. Cessation of contraception after this point should be discussed with a responsible physician. Periodic abstinence, the rhythm method, and the withdrawal method are not acceptable methods of contraception.
Exclusion
- Diabetes
- Pregnancy/lactation
- Hgb \<11
- Current GI obstruction or chronic diarrhea
- Subjects who are not within the age range of 18- 65 years.
- Evidence of active cardiorespiratory, hepatic, gastrointestinal or renal disease.
- History of allergy to the administered drugs.
- History of, or any existing condition that, in the opinion of the investigator, would interfere with evaluation of the investigational product, put the subject at risk, influence the subject's ability to participate or affect the interpretation of the results of the study and/or any subject unable or unwilling to follow study procedures.
- Substance dependence or history of alcohol abuse and/or excess alcohol intake
- Patients on ketogenic diet
- Prisoners or institutionalized individuals
- AST (SGOT) \> 3 times upper limit of normal
- ALT (SGPT) \> 3 times upper limit of normal
- History of clinical hypoglycemia documents based on Whipples' triad (ONLY for Aim 2)
Key Trial Info
Start Date :
December 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2030
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT07212868
Start Date
December 1 2025
End Date
June 30 2030
Last Update
December 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Texas Diabetes Institute - University Health System
San Antonio, Texas, United States, 78207
2
University of Texas San Antonio
San Antonio, Texas, United States, 78229